Physician profile
Ram Vasudevan
NPI 1821081688
$2,688.46
in general payments reported to CMS, 2019-2025
16 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $127 · 2021: $96.17 · 2022: $51.23 · 2023: $186 · 2024: $1,522 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,486 · Food and Beverage: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,486.14 |
| Food and Beverage | $738.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,035.29 | 2023-2025 | Aveir, Assurity, Jot Dx |
| Boston Scientific Corporation | $173.58 | 2020-2025 | Watchman Flx |
| Medtronic Vascular, INC. | $137.42 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $64.54 | 2019-2025 | Lifevest |
| Cvrx, INC. | $45.62 | 2024-2025 | Barostim Neo System |
| Genentech USA, INC. | $44.36 | 2020-2022 | |
| Foundation Medicine, INC. | $42.07 | 2019-2021 | |
| Pfizer INC. | $23.98 | 2024 | |
| Fennec Pharmaceuticals, INC. | $23.65 | 2025 | Fyarro |
| Alnylam Pharmaceuticals INC. | $21.38 | 2025 | Givlaari |
| Gilead Sciences, INC. | $19.79 | 2022 | |
| Merck Sharp & Dohme LLC | $18.33 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.43 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.08 | 2021 | |
| Medtronic, INC. | $11.94 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,078,505.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ram Vasudevan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.